Want to see IN:ANURAS full AI Analyst Report?
Top Page
Anupam Rasayan India Ltd.
(ANURAS)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹1,147.00
▼(-8.98% Downside)
Action:Reiterated
Date:08/25/26
The score is held back primarily by weak cash generation (recurring negative free cash flow) and a high valuation (P/E ~81.6). These risks are partially offset by the FY2026 revenue rebound and still-healthy operating margins, while technical indicators are mixed with modest momentum but limited longer-term trend support.
Positive Factors
Specialty chemicals platform
The company operates in specialty chemicals through custom synthesis and contract manufacturing of complex intermediates, serving agrochemicals, pharmaceuticals, personal care, and pigments. This diversified, process-focused model supports customer integration and creates a durable platform for repeat industrial demand.
Negative Factors
Weak free cash flow
Recurring negative free cash flow, reaching about -3.6B in FY2026, shows that accounting profitability is not converting into sufficient surplus cash. Continued heavy reinvestment or working-capital drag can increase funding needs and limit flexibility to finance growth internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty chemicals platform
The company operates in specialty chemicals through custom synthesis and contract manufacturing of complex intermediates, serving agrochemicals, pharmaceuticals, personal care, and pigments. This diversified, process-focused model supports customer integration and creates a durable platform for repeat industrial demand.
Read all positive factors
Anupam Rasayan India Ltd. (ANURAS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹129.99B
Dividend Yield0.13%
Average Volume (3M)19.44K
Price to Earnings (P/E)74.3
Beta (1Y)0.73
Revenue Growth51.77%
EPS Growth36.90%
CountryIN
Employees2,606
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)15.38
Shares Outstanding113,849,840
10 Day Avg. Volume8,588
30 Day Avg. Volume19,441
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)4.16
Price to Sales (P/S)5.87
P/FCF Ratio-38.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)21.23
Revenue Forecast (FY)₹27.26B
Anupam Rasayan India Ltd. Business Overview & Revenue Model
Company Description
Anupam Rasayan India Ltd., established in Surat, India, in 1984, specializes in the custom synthesis and production of specialty chemicals. The company manufactures a diverse range of life science-oriented chemicals, including intermediates and ac...
Anupam Rasayan India Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.35B | 23.65B | 14.42B | 14.80B | 16.02B | 10.74B |
| Gross Profit | 9.27B | 8.16B | 8.22B | 8.51B | 8.85B | 7.02B |
| EBITDA | 5.76B | 5.43B | 4.07B | 3.87B | 4.32B | 3.05B |
| Net Income | 1.75B | 1.70B | 933.49M | 1.29B | 1.81B | 1.52B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 80.13B | 52.69B | 46.02B | 37.78B | 28.91B |
| Cash, Cash Equivalents and Short-Term Investments | 4.11B | 4.11B | 1.35B | 3.48B | 6.67B | 618.77M |
| Total Debt | 0.00 | 18.67B | 13.73B | 10.70B | 8.22B | 8.36B |
| Total Liabilities | -46.30B | 33.83B | 21.87B | 16.71B | 12.70B | 11.64B |
| Stockholders Equity | 46.30B | 33.34B | 28.50B | 27.61B | 23.73B | 17.27B |
Cash Flow | ||||||
| Free Cash Flow | 3.28B | -3.57B | -4.40B | -6.57B | 713.03M | -3.18B |
| Operating Cash Flow | 5.35B | 1.99B | -301.25M | 590.32M | 2.92B | -1.71B |
| Investing Cash Flow | -2.53B | -8.21B | -3.30B | -3.92B | -5.23B | -4.12B |
| Financing Cash Flow | 182.51M | 7.57B | 2.23B | 3.95B | 3.71B | 3.84B |
Anupam Rasayan India Ltd. Technical Analysis
Negative
1260.10
Price Trends
1188.57
Negative
1217.62
Negative
1256.13
Negative
Market Momentum
-11.77
Negative
47.27
Neutral
75.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANURAS, the sentiment is Negative. The current price of 1260.1 is above the 20-day moving average (MA) of 1143.60, above the 50-day MA of 1188.57, and above the 200-day MA of 1256.13, indicating a bearish trend. The MACD of -11.77 indicates Negative momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 75.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ANURAS.
Anupam Rasayan India Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹81.33B | 36.11 | ― | 0.63% | 5.11% | 20.64% | |
62 Neutral | ₹147.89B | 19.18 | ― | 0.60% | 18.15% | 42.38% | |
61 Neutral | ₹215.08B | 90.95 | ― | ― | 33.79% | 34.24% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹129.99B | 74.35 | ― | 0.13% | 51.77% | 36.90% | |
53 Neutral | ₹89.05B | 25.14 | ― | 0.89% | 15.41% | 21.76% | |
47 Neutral | ₹157.96B | 29.74 | ― | 0.23% | 27.05% | 123.98% |
* General Sector Average
IN:ANURAS
Anupam Rasayan India Ltd.
1,141.80
70.07
6.54%
IN:AARTIIND
AARTI Industries Ltd
435.45
56.20
14.82%
IN:AETHER
Aether Industries Ltd.
1,620.45
867.10
115.10%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,590.10
-261.45
-14.12%
IN:ATUL
Atul Limited
5,023.05
-714.42
-12.45%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
559.05
-125.35
-18.32%
Anupam Rasayan India Ltd. Corporate Events
Anupam Rasayan Secures Majority Control in Bliss GVS Pharma
Sep 28, 2026
Anupam Rasayan India Ltd. has completed the acquisition of a controlling stake in Bliss GVS Pharma Ltd., culminating a series of transactions under a previously announced share purchase agreement and open offer. Following on-market purchases and t...
Anupam Rasayan Executes Security Documents Backing MVCPL Debentures
Sep 23, 2026
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd. and Catalyst Trusteeship Ltd., as part of a security package linked to debentures issued by MVCPL. The move formalizes arrangements under a pr...
Anupam Rasayan Pledges MVCPL Stake and Issues Corporate Guarantee for Debenture Structure
Sep 23, 2026
Anupam Rasayan India Ltd. has executed a debenture trust deed involving Mates Visa Consultancy Pvt. Ltd., Catalyst Trusteeship Ltd., and the debenture holders, formalising security arrangements around MVCPL’s debentures. As part of this stru...
Anupam Rasayan Raises INR 145 Crore via Secured Debenture Issue
Sep 21, 2026
Anupam Rasayan India Ltd. has allotted 14,500 senior secured, rated, unlisted, redeemable non-convertible debentures with a face value of INR 1,00,000 each, raising INR 145 crore from Aditya Birla Capital Ltd. The issuance, executed through a debe...
Anupam Rasayan Board Clears INR 160 Crore NCD Issue for Debt Refinancing
Sep 19, 2026
Anupam Rasayan India Ltd.’s board has approved the private placement of up to 16,000 secured, rated, unlisted, redeemable non-convertible debentures, with a total size not exceeding INR 160 crore. The debentures will be issued in demateriali...
Anupam Rasayan to Raise ₹160 Crore via Secured Non-Convertible Debentures
Sep 19, 2026
Anupam Rasayan India Ltd.’s board has approved the issuance of up to 16,000 secured, rated, unlisted and redeemable non-convertible debentures, each with a nominal value of ₹100,000, for a total amount not exceeding ₹160 crore on...
Anupam Rasayan Files Q1 FY27 Results, Appoints New COO
Aug 14, 2026
Anupam Rasayan India Ltd. reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a board meeting held on August 14. The results have undergone a limited review by the statutory auditor, ...
Anupam Rasayan Elevates Ravi Desai to Chief Operating Officer
Aug 14, 2026
Anupam Rasayan India Ltd. has appointed Ravi Desai as Chief Operating Officer, effective August 14, 2026, following approval by the board based on the Nomination and Remuneration Committee’s recommendation. Desai, who has been with the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.